Breaking News Instant updates and real-time market news.

MRK

Merck

09:29
10/10/16
10/10
09:29
10/10/16
09:29

Merck trades to fresh 52-week high in pre-market

The shares were last at $64.75, edging a fresh 52-week high. At that price next resistance is at $66. Support is at $64, the prior 52-week high.

  • 25

    Oct

  • 06

    Nov

MRK Merck

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

ENR

Energizer

$59.11

7.49 (14.51%)

05:47
01/17/18
01/17
05:47
01/17/18
05:47
Downgrade
Energizer rating change  »

Energizer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

ABB

ABB

$28.07

-0.02 (-0.07%)

05:46
01/17/18
01/17
05:46
01/17/18
05:46
Upgrade
ABB rating change  »

ABB upgraded to Hold from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Recommendations
Celgene, Juno Therapeutics analyst commentary  »

Jefferies believes $8B…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

DF

Dean Foods

$11.28

0.01 (0.09%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Upgrade
Dean Foods rating change  »

Dean Foods upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

05:44
01/17/18
01/17
05:44
01/17/18
05:44
Downgrade
Apple rating change  »

Apple downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

RGC

Regal Entertainment

$22.90

-0.07 (-0.30%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Downgrade
Regal Entertainment rating change  »

Regal Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PII

Polaris Industries

$127.90

-2.13 (-1.64%)

05:43
01/17/18
01/17
05:43
01/17/18
05:43
Upgrade
Polaris Industries rating change  »

Polaris Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

DISH

Dish

$47.99

-1.49 (-3.01%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Downgrade
Dish rating change  »

Dish downgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

LBTYA

Liberty Global

$36.56

-0.31 (-0.84%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

, MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Hot Stocks
Ingersoll-Rand, Mitsubishi Electric establish JV for ductless and VRF systems »

Ingersoll-Rand (IR) and…

IR

Ingersoll-Rand

$90.26

-0.84 (-0.92%)

MIELY

Mitsubishi Electric

$36.44

0.035 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

EGHT

8x8, Inc.

$15.30

0.05 (0.33%)

05:42
01/17/18
01/17
05:42
01/17/18
05:42
Upgrade
8x8, Inc. rating change  »

8x8, Inc. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 25

    Jan

NVS

Novartis

$86.73

0.08 (0.09%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Hot Stocks
Novartis granted FDA priority review for Kymriah »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 08

    Feb

  • 16

    Feb

  • 23

    Apr

  • 17

    May

SKX

Skechers

$37.91

-0.64 (-1.66%)

05:38
01/17/18
01/17
05:38
01/17/18
05:38
Recommendations
Skechers analyst commentary  »

Skechers price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$100.69

-0.18 (-0.18%)

05:36
01/17/18
01/17
05:36
01/17/18
05:36
Hot Stocks
Walmart launches opioid disposal solution »

In an effort to help curb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

BLL

Ball Corp.

$38.39

0.49 (1.29%)

05:35
01/17/18
01/17
05:35
01/17/18
05:35
Upgrade
Ball Corp. rating change  »

Ball Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

PBYI

Puma Biotechnology

$90.85

-8.4 (-8.46%)

05:34
01/17/18
01/17
05:34
01/17/18
05:34
Recommendations
Puma Biotechnology analyst commentary  »

Puma Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADTN

Adtran

$19.50

-0.2 (-1.02%)

05:30
01/17/18
01/17
05:30
01/17/18
05:30
Earnings
Adtran reports Q4 adj. EPS 5c, consensus (4c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

PSTG

Pure Storage

$16.16

-0.31 (-1.88%)

05:27
01/17/18
01/17
05:27
01/17/18
05:27
Upgrade
Pure Storage rating change  »

Pure Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

PSDO

Presidio

$17.74

-0.96 (-5.13%)

05:25
01/17/18
01/17
05:25
01/17/18
05:25
Downgrade
Presidio rating change  »

Presidio downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.